Latest news and press releases about Outlook Therapeutics, Inc. (OTLK): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials.
Price
| Price | $0.68 |
| Market Cap | $127M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -1.60 |
| EV / EBITDA | -2.05 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 222.01% |
| Return on Invested Capital | -343.68% |
| Return on Assets | -233.43% |
| Gross Margin | 195.64% |
| Operating Margin | 4783.05% |
| Net Margin | 5254.81% |
Related companies: COEP · CUE · EQ · HOWL · IOBT · IPSC · MDCX
Explore sector: Healthcare · Biotechnology
More sections of OTLK: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks